Century Therapeutics, Inc.
IPSC
$2.21
$0.094.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | 12,667.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | 12,667.72% |
| Cost of Revenue | -35.65% | -32.95% | -17.27% | -1.33% | 13.49% |
| Gross Profit | -120.71% | 21.85% | 14.79% | -1.55% | 465.97% |
| SG&A Expenses | -2.88% | -26.56% | -18.16% | -6.03% | -1.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.60% | -31.59% | -17.48% | -2.43% | 9.52% |
| Operating Income | -134.49% | 22.99% | 15.60% | 0.26% | 336.16% |
| Income Before Tax | -128.27% | 43.90% | -10.21% | -4.35% | 372.83% |
| Income Tax Expenses | -- | -103.83% | -- | -- | -- |
| Earnings from Continuing Operations | -128.27% | 46.85% | -10.24% | -4.27% | 372.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.27% | 46.85% | -10.24% | -4.27% | 372.82% |
| EBIT | -134.49% | 22.99% | 15.60% | 0.26% | 336.16% |
| EBITDA | -129.16% | 26.32% | 16.70% | -0.54% | 374.75% |
| EPS Basic | -112.57% | 48.00% | -8.00% | 0.74% | 297.56% |
| Normalized Basic EPS | -113.67% | 21.75% | 13.28% | 0.67% | 296.98% |
| EPS Diluted | -112.57% | 48.50% | -8.11% | 0.03% | 297.56% |
| Normalized Diluted EPS | -113.68% | 21.75% | 13.28% | 0.67% | 296.80% |
| Average Basic Shares Outstanding | 124.92% | 2.19% | 2.08% | 5.05% | 38.08% |
| Average Diluted Shares Outstanding | 124.71% | 2.19% | 2.08% | 5.05% | 38.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |